BlackRock
IKT icon

BlackRock’s Inhibikase Therapeutics IKT Stock Holding History

BlackRock’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Buy
7,768,057
+1,464,624
+23% +$2.62M ﹤0.01% 3426
2026
Q1 		$10.6M Buy
6,303,433
+2,997,859
+91% +$5.32M ﹤0.01% 3471
2025
Q4 		$6.78M Buy
3,305,574
+230,388
+7% +$367K ﹤0.01% 3698
2025
Q3 		$4.98M Buy
3,075,186
+347,018
+13% +$601K ﹤0.01% 3786
2025
Q2 		$5.32M Buy
2,728,168
+2,304,189
+543% +$4.51M ﹤0.01% 3744
2025
Q1 		$929K Buy
423,979
+88,519
+26% +$222K ﹤0.01% 4213
2024
Q4 		$1.09M Buy
+335,460
New +$837K ﹤0.01% 4202
2022
Q2 		– Sell
-8,583
Closed -$76K – 5909
2022
Q1 		$76K Sell
8,583
-424
-5% -$3.41K ﹤0.01% 5342
2021
Q4 		$79K Buy
9,007
+550
+7% +$6.07K ﹤0.01% 5327
2021
Q3 		$96K Buy
8,457
+6,195
+274% +$83.8K ﹤0.01% 5146
2021
Q2 		$38K Buy
2,262
+2,167
+2,281% +$63.8K ﹤0.01% 5223
2021
Q1 		$3K Buy
+95
New +$3.85K ﹤0.01% 5179

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock's IKT Position: Q2 2026 in Review

BlackRock increased its Inhibikase Therapeutics (IKT) stake by 23% in Q2 2026, buying an estimated $2.62M and bringing the position to 7,768,057 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

BlackRock first reported a position in IKT in Q1 2021 and has held it in 12 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • BlackRock held 7,768,057 shares of Inhibikase Therapeutics worth $15.8M as of Q2 2026.
  • BlackRock bought 1,464,624 Inhibikase Therapeutics shares in Q2 2026, an estimated $2.62M.
  • Inhibikase Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3426 holding.
  • BlackRock first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.